106 related articles for article (PubMed ID: 27815492)
1. Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery.
Wang Z; Jay CM; Evans C; Kumar P; Phalon C; Rao DD; Senzer N; Nemunaitis J
Toxicol Sci; 2017 Feb; 155(2):400-408. PubMed ID: 27815492
[TBL] [Abstract][Full Text] [Related]
2. In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein.
Phadke AP; Jay CM; Wang Z; Chen S; Liu S; Haddock C; Kumar P; Pappen BO; Rao DD; Templeton NS; Daniels EQ; Webb C; Monsma D; Scott S; Dylewski D; Frieboes HB; Brunicardi FC; Senzer N; Maples PB; Nemunaitis J; Tong AW
DNA Cell Biol; 2011 Sep; 30(9):715-26. PubMed ID: 21612405
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of local injection of lentivirus-delivered stathmin1 and stathmin1 shRNA in human gastric cancer xenograft mouse.
Akhtar J; Wang Z; Yu C; Zhang ZP
J Gastroenterol Hepatol; 2014 Sep; 29(9):1685-91. PubMed ID: 24720379
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
Barve M; Wang Z; Kumar P; Jay CM; Luo X; Bedell C; Mennel RG; Wallraven G; Brunicardi FC; Senzer N; Nemunaitis J; Rao DD
Mol Ther; 2015 Jun; 23(6):1123-1130. PubMed ID: 25619726
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
[TBL] [Abstract][Full Text] [Related]
6. Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference.
Rao DD; Maples PB; Senzer N; Kumar P; Wang Z; Pappen BO; Yu Y; Haddock C; Jay C; Phadke AP; Chen S; Kuhn J; Dylewski D; Scott S; Monsma D; Webb C; Tong A; Shanahan D; Nemunaitis J
Cancer Gene Ther; 2010 Nov; 17(11):780-91. PubMed ID: 20596090
[TBL] [Abstract][Full Text] [Related]
7. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.
Han ZX; Wang HM; Jiang G; Du XP; Gao XY; Pei DS
Cancer Biother Radiopharm; 2013 Jun; 28(5):398-405. PubMed ID: 23496232
[TBL] [Abstract][Full Text] [Related]
8. Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma.
Wang S; Akhtar J; Wang Z
Tumour Biol; 2015 Sep; 36(10):7797-806. PubMed ID: 25944168
[TBL] [Abstract][Full Text] [Related]
9. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of liposomal l-OHP and PEGylated TS shRNA-lipoplex: A novel approach to enhance anti-tumor efficacy and reduce the immunogenic response to RNAi molecules.
Alaaeldin E; Abu Lila AS; Ando H; Fukushima M; Huang CL; Wada H; Sarhan HA; Khaled KA; Ishida T
J Control Release; 2017 Jun; 255():210-217. PubMed ID: 28461099
[TBL] [Abstract][Full Text] [Related]
11. High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.
Bao P; Yokobori T; Altan B; Iijima M; Azuma Y; Onozato R; Yajima T; Watanabe A; Mogi A; Shimizu K; Nagashima T; Ohtaki Y; Obayashi K; Nakazawa S; Bai T; Kawabata-Iwakawa R; Asao T; Kaira K; Nishiyama M; Kuwano H
Ann Surg Oncol; 2017 Dec; 24(13):4017-4024. PubMed ID: 28933054
[TBL] [Abstract][Full Text] [Related]
12. Tissue distribution and cancer growth inhibition of magnetic lipoplex-delivered type 1 insulin-like growth factor receptor shRNA in nude mice.
Kong M; Li X; Wang C; Ding C; Dong A; Duan Q; Shen Z
Acta Biochim Biophys Sin (Shanghai); 2012 Jul; 44(7):591-6. PubMed ID: 22626974
[TBL] [Abstract][Full Text] [Related]
13. Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer.
Kang W; Tong JH; Chan AW; Lung RW; Chau SL; Wong QW; Wong N; Yu J; Cheng AS; To KF
PLoS One; 2012; 7(3):e33919. PubMed ID: 22470493
[TBL] [Abstract][Full Text] [Related]
14. Reduced STMN1 expression induced by RNA interference inhibits the bioactivity of pancreatic cancer cell line Panc-1.
Li J; Hu GH; Kong FJ; Wu KM; He B; Song K; Sun WJ
Neoplasma; 2014; 61(2):144-52. PubMed ID: 24299310
[TBL] [Abstract][Full Text] [Related]
15. Effects of stathmin 1 silencing by siRNA on sensitivity of esophageal cancer cells Eca-109 to paclitaxel.
Zhu HW; Jiang D; Xie ZY; Zhou MH; Sun DY; Zhao YG
Genet Mol Res; 2015 Dec; 14(4):18695-702. PubMed ID: 26782519
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.
Rao DD; Luo X; Wang Z; Jay CM; Brunicardi FC; Maltese W; Manning L; Senzer N; Nemunaitis J
PLoS One; 2018; 13(5):e0193644. PubMed ID: 29851957
[TBL] [Abstract][Full Text] [Related]
17. The role of tissue macrophages in the induction of proinflammatory cytokine production following intravenous injection of lipoplexes.
Sakurai F; Terada T; Yasuda K; Yamashita F; Takakura Y; Hashida M
Gene Ther; 2002 Aug; 9(16):1120-6. PubMed ID: 12140741
[TBL] [Abstract][Full Text] [Related]
18. RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model.
Byrne FL; Yang L; Phillips PA; Hansford LM; Fletcher JI; Ormandy CJ; McCarroll JA; Kavallaris M
Oncogene; 2014 Feb; 33(7):882-90. PubMed ID: 23396365
[TBL] [Abstract][Full Text] [Related]
19. A simplified method for manufacturing RNAi therapeutics for local administration.
Ando H; Abu Lila AS; Fukushima M; Matsuoka R; Shimizu T; Okuhira K; Ishima Y; Huang CL; Wada H; Ishida T
Int J Pharm; 2019 Jun; 564():256-262. PubMed ID: 31015002
[TBL] [Abstract][Full Text] [Related]
20. Stathmin 1 is a potential novel oncogene in melanoma.
Chen J; Abi-Daoud M; Wang A; Yang X; Zhang X; Feilotter HE; Tron VA
Oncogene; 2013 Mar; 32(10):1330-7. PubMed ID: 22665054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
